Faculty profile

Mitchell Sabloff

Back to faculty

Assistant ProfessorDepartment of MedicineUniversity of Ottawa

Mitchell Sabloff

Assistant Professor

Department of Medicine

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
16 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2015.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

568

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Cell Fate Chip-Sequencing Gene Regulatory Networks Hematopoiesis Hematopoietic Stem Cells Leukemia Polycomb Transcriptomics

Latest papers

Grip strength is associated with overall survival in myelodysplastic syndrome.
Blood advances · 2026
Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.
Haematologica · 2026
Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus
Current Oncology · 2026

All 58 publications

Latest funding

Dissecting the roles of the Polycomb protein MTF2 in leukemogenesis
CIHR · 2022 · Co-investigator
$956,250
Targeting the epigenetic state of refractory and relapsing acute myeloid leukemia
CIHR · 2018 · Co-investigator
$1,500,000
Molecular Targeting of Human Acute Myeloid Leukemia and Bone Marrow Regeneration
CIHR · 2017 · Co-investigator
$4,162,215

All 8 grants and awards

58 publications.

Grip strength is associated with overall survival in myelodysplastic syndrome.

Chornenki NLJ, Mozessohn L, Chodirker L, Chow S, Kennedy JA, England JT, Cheung MC, Geddes M, Sabloff M, Christou G, Fulcher J, Rajendra A, St Hilaire E, Finn N, Zhu NY, Leber B, Garcia-Horton A, Trottier AM, Shamy A, Leitch HA, Houston BL, Landego I, Yee KWL, Nevill TJ, Storring J, Elemary M, Habib LA, Delage R, Siddiqui M, Zhang L, Buckstein RJ

Blood advances2026

DOI: 10.1182/bloodadvances.2026021036 PMID: 42782304

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

Murphy T, Zhang B, Zhang T, King I, Capo-Chichi J-M, Gupta V, Maze D, McNamara CJ, Minden MD, Schimmer AD

Haematologica20266 citations

DOI: 10.3324/haematol.2025.287777

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus

Schuh AC, Chornenki N, Elemary MA, Elsawy M, Houston BL, Leber B, Mozessohn L, Sabloff M, Salter B, Sanford D

Current Oncology2026

DOI: 10.3390/curroncol33070429

Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective.

Saiyin T, Christou G, Sabloff M, Crosbie T, Nguyen-Tham KM, Fulcher J

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol32040213 PMID: 40277769

Patient and Healthcare Professional Reflections on Consenting for Extra Bone Marrow Samples to a Biobank for Research-A Qualitative Study.

Nicholls SG, Camilleri E, Chesser T, Davis G, Godard K, Fox G, Gordon MJ, Lewis KB, Lepage J, Motalo O, Nuttall W, Peleshok C, Ito CY, Villeneuve PJA, Sabloff M

Current oncology (Toronto, Ont.)2025Senior author

DOI: 10.3390/curroncol32030179 PMID: 40136383

Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.

Gyurkocza B, Nath R, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco JJ, Jamieson K, Silverman M, Van Besien K, Schuster M, Law AD, Larkin K, Pandit-Taskar N, Rowley SD, Munshi P, Cook R, Levy MY, Lazarus HM, Sandmaier BM, Pagel JM, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025

DOI: 10.1200/jco.23.02018 PMID: 39298738

Improvement in quality of life in MDS patients who become transfusion independent after treatment

Wan BA, Alibhai SMH, Chodirker L, Mozessohn L, Geddes M, Zhu N, Trottier AM, St-Hilaire E, Finn N, Leber B

Leukemia and Lymphoma20255 citations

DOI: 10.1080/10428194.2024.2422844

Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50-70 year old AML patients.

Brune M, Kiss T, Anderson H, Nicklasson M, Delage R, Finke J, Gedde-Dahl T, Hébert J, Höglund M, Kaare A, Lazarevic V, Möllgård L, Remes K, Ritchie D, Spyridonidis A, Sabloff M, Spearing R, Wallhult E, Ljungman P

Bone marrow transplantation2024

DOI: 10.1038/s41409-024-02408-x PMID: 39223244

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating M-M

The Lancet Haematology202498 citations

DOI: 10.1016/s2352-3026(23)00338-1

Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario

Verville L, McKay C, Kouroukis T, Apostolovski S, Sabloff M, Buckstein R, Kennedy K, Yee K, Eakins A, Bredeson C

Current Oncology20241 citations

DOI: 10.3390/curroncol31080347

Dissecting the roles of the Polycomb protein MTF2 in leukemogenesis

Co-investigatorCIHR2022Project Grant

Principal investigators: Stanford, William L

Keywords: Acute Myeloid Leukemia (Aml); Chemoresistance; Chromatin Immunoprecipitation; Dna Damage Response; Epigenetics; Gene Regulatory Networks; Hematopoiesis; Transcriptomics

$956,250

Targeting the epigenetic state of refractory and relapsing acute myeloid leukemia

Co-investigatorCIHR2018Operating Grant: Epigenetics Clinical Translation

Principal investigators: Stanford, William L; Brand, Marjorie C; Couture, Jean-François; Dilworth, Jeffrey J; Ito, Caryn

Keywords: Acute Myeloid Leukemia (Aml); Drug Development; Epigenetics; Polycomb Repressive Complex 2; Trithorax

$1,500,000

Molecular Targeting of Human Acute Myeloid Leukemia and Bone Marrow Regeneration

Co-investigatorCIHR2017Foundation Grant

Principal investigators: Bhatia, Mickie

Keywords: Acute Leukemia; Bone Marrow; Disease Biomarkers; Drug Development; Hematopoiesis; Hematopoietic Stem Cells; Leukemic Stem Cells; Pre-Clinical Modeling; Therapeutic Approaches; Translational Science

$4,162,215

Relapse-induced (ri) Leukemia Stem Cells or "riLSCs"

Co-investigatorCIHR2016Project Grant

Principal investigators: Bhatia, Mickie

Keywords: Acute Myeloid Leukemia; Chemotherapy Induced Relapse; In Vitro Evaluation; In Vivo Efficacy Testing; Repurposed Drug Discovery

$1,040,400

Platelet Transfusions in Hematopoietic Stem cell Transplantation - The PATH Study

Co-investigatorCIHR2015Operating Grant

Principal investigators: Tay, Jason; Maze, Dawn; Tinmouth, Alan T

Keywords: Hematopoieitic Stem Cell Transplantation; Platelets; Transfusion; Tranxaemic Acid

$213,400

The role of PCL2/PRC2 in hematopoietic stem cells and leukemia

Principal investigatorCIHR2015Operating Grant

Principal investigators: Stanford, William L; Ito, Caryn; Perkins, Theodore J; Sabloff, Mitchell

Keywords: Cell Fate; Chip-Sequencing; Gene Regulatory Networks; Hematopoiesis; Hematopoietic Stem Cells; Leukemia; Polycomb; Transcriptomics; Tumor Suppressor; Xenotransplantation

$1,163,874

Safety and Efficacy of a Therapeutic Platelet Transfusion Strategy in Outpatients

Co-investigatorCIHR2011Operating Grant

Principal investigators: Tinmouth, Alan T

Keywords: Acute Leukemia; Bleeding; Myelodysplastic Syndromes; Pilot/Feasibility Study; Platelet Transfusions; Quality Of Life; Randomized Controlled Trial

$150,031

Myelodysplastic Syndromes (MDS) in Canada: A national prospective study of the epidemiology, quality of life and impact of co-morbidity/frailty on disease outcome

Co-investigatorCIHR2011Operating Grant - PA: Cancer Research (bridge funding)

Principal investigators: Buckstein, Rena J

Keywords: Co-Morbidity; Epidemiology; Frailty; Myelodysplastic Syndromes; Prospective Cross Sectional Assessment; Quality Of Life; Registry And Database

$100,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Mitchell Sabloff

Research

Latest papers

Latest funding

Grip strength is associated with overall survival in myelodysplastic syndrome.

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus

Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective.

Patient and Healthcare Professional Reflections on Consenting for Extra Bone Marrow Samples to a Biobank for Research-A Qualitative Study.

Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.

Improvement in quality of life in MDS patients who become transfusion independent after treatment

Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50-70 year old AML patients.

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario

Frequent collaborators

Christopher Bredeson

David Allan

Lothar Huebsch

Brian Leber

Harold Atkins

Lisa Chodirker

Natasha Kekre

Lee Mozessohn

Jason Tay

Dawn Maze

Dean Fergusson

Alissa Visram

Alan Tinmouth

Marjorie Brand

Ning Liu

Nicole Mittmann

Versha Banerji

Ronan Foley

Brian Hutton

Kednapa Thavorn

Stephen Juvet

Kednapa Thavorn

Anand Ghanekar

Gonzalo Sapisochin

Timothy Ramsay

Markus Selzner

Antonio Giulivi

Sandra Cohen

Nazia Selzner

Mick Bhatia

Caryn Ito

Tom Kouroukis

Clinton Campbell

Catherine Ross

Mark Cattral

Shabbir Alibhai

Ian Mcgilvray